問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



MacKay Memorial Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 251New Taipei CityDanshuei

Recruiting Trial

28Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

257Cases

2018-09-01 - 2022-05-25

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 2

  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    Mirikizumab

Participate Sites
12Sites

Recruiting10Sites

Terminated1Sites

周仁偉
China Medical University Hospital-Taipei

未分科

2017-08-01 - 2018-03-02

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated6Sites

2017-12-01 - 2018-06-03

Phase III

A Phase 1b/3 Multicenter, Randomized Trial of Talimogene Laherparepvec in combination with Pembrolizumab for theTreatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Condition/Disease

    Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    IMLYGIC

Participate Sites
6Sites

Terminated6Sites

2018-03-23 - 2020-04-14

Phase III

A Multicenter, Multiple-dose, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide (AMG 416) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism

  • Condition/Disease

    Secondary Hyperparathyroidism/Hemodialysis

  • Test Drug

    Parsabiv

Participate Sites
13Sites

Terminated13Sites

2017-09-06 - 2021-05-31

Phase III

A Phase 3, Long-term Active Treatment Extension Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

  • Condition/Disease

    Crohn's Disease

  • Test Drug

    Mongersen (GED-0301)

Participate Sites
7Sites

Terminated6Sites

2017-03-01 - 2021-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2017-08-03 - 2018-12-31

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects with Active Crohn’s Disease.

  • Condition/Disease

    Crohn Disease

  • Test Drug

    Mongersen (GED-0301)

Participate Sites
5Sites

Terminated5Sites

2017-03-01 - 2019-08-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2014-12-01 - 2017-07-21

Phase III

A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients with Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) Trial

  • Condition/Disease

    Cardiovascular Disease

  • Test Drug

    AMG 145

Participate Sites
8Sites

Terminated8Sites

2014-12-01 - 2018-06-30

Phase II

A Randomized Phase 2A/2B, Multicenter Study to Compare the Efficacy and Safety of ASLAN001 in Combination with Capecitabine to Lapatinib in Combination with Capecitabine in Patients with HER-2-Positive Metastatic Breast Cancer that has Failed on Prior Trastuzumab Therapy

  • Condition/Disease

    Breast Cancer

  • Test Drug

    ASLAN001

Participate Sites
7Sites

Terminated6Sites

Study ended1Sites

王惠暢
China Medical University Hospital

Division of General Surgery

1 14 15 16 17 18 26
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB